Snapshot from Aug 25, 2026 at 07:00 UTC. For live data and tracking: View Live

France & Gilead Sciences

4 shared events · Importance 4 · Last updated Jul 31, 2026

Importance
4
Shared Events
4
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
42
International
France: One of the Western countries that slashed foreign assistance, contributing to Joint United Nations Programme on HIV/AIDS funding loss.
Gilead Sciences: Developed lenacapavir, a highly effective HIV prevention injectable; faces potential revenue impact from generic production in South Africa.
Jul 21, 2026 · 6 articles
35
International
France: Reduced HIV funding as part of European cuts, contributing to the overall decline.
Gilead Sciences: Facing pressure to expand access to lenacapavir; its pricing and licensing decisions are under scrutiny.
Jul 21, 2026 · 68 articles
32
Accidents
France: Confirmed one case in a doctor who recovered; no further spread.
Gilead Sciences: Supplying remdesivir for clinical trials; potential positive impact if treatment proves effective.
Mar 09, 2018 · 314 articles
28
Accidents
France: Reported first case outside Africa in a humanitarian worker who recovered.
Gilead Sciences: Developed obeldesivir, the antiviral being tested in the EBO-PEP trial.
Jul 06, 2026 · 410 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how France and Gilead Sciences interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.